BRAF and Barrett adenocarcinoma: A previous study showed that RAS or BRAF mutations were detected in approximately 32% of all Barrett’s adenocarcinomas, which indicated that disruption of the MAPK kinase pathway is a frequent but also early event in the development of Barrett’s adenocarcinoma27.